Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Brought to you by:
Cell & Gene Therapy
Biotech
Eli Lilly pays $1B upfront to buy gene editing partner Verve
Eli Lilly confirms its buyout of Verve after an M&A report by the Financial Times Monday.
James Waldron
Jun 17, 2025 4:35am
Fierce Pharma
2nd patient dies after Sarepta's DMD gene therapy Elevidys
Jun 16, 2025 10:58am
J&J lymphoma CAR-T hits 100% ORR in 10 patients
Jun 13, 2025 1:22pm
SpliceBio secures $135M series B for eye gene therapy trials
Jun 11, 2025 3:00am
To Gilead's new CMO, pipeline diversification is key
Jun 9, 2025 10:00am
As investors pivot from cell therapy, Immatics keeps the faith
Jun 6, 2025 3:50am
More News
At cell and gene roundtable, officials pledge to slash regulations
Jun 5, 2025 2:50pm
RegenXBio links DMD gene therapy to improved outcomes
Jun 5, 2025 8:52am
Cullinan's $700M pact for BCMA bispecific to pair with other TCE
Jun 5, 2025 4:38am
Ernexa's stem cell therapy shrinks ovarian tumors in mice
Jun 2, 2025 2:30pm
See more stories
